drugset / Trial / NCT01498939

Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects

NCT01498939

Phase 1 Completed 20 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetics after a single dose of insulin detemir in healthy Chinese male subjects.

Timeline

Start
2007-08
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin detemir Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Subject insulin detemir Protein / enzyme biologic 0.4 iu/kg Subcutaneous
Subject insulin detemir Protein / enzyme biologic 0.8 iu/kg Subcutaneous

Indications